US Study Reveals CP-GEP's Profound Impact on Stratifying Melanoma Patients for Long-Term Survival
ROTTERDAM, Netherlands and SAN DIEGO, Nov. 6, 2023 . SkylineDx, an innovative molecular diagnostics company, is pleased to announce the forthcoming presentation of an impactful poster by Dr M.E. Egger at the upcoming Society for Melanoma Research... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 7, 2023 Category: Pharmaceuticals Source Type: clinical trials
Prospective Assessment of HPV Associated Anogenital Pathology in Female Patients and Female Partners of Patients With Confirmed HPV Associated Oropharyngeal Carcinoma, PAP-OP Study
Conditions: Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Conditions: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Squamous Cell Carcinoma; Stage IV Pancreatic Cancer AJCC v8 Interventions: Drug: Nab paclitaxel; Drug: Gemcitabine; Drug: Cisplatin; Procedure: Magnetic Resonance Imaging; Procedure: Computed Tomography; Procedure: Biospecimen Collection Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
Conditions: Melanoma Interventions: Drug: Nivolumab Sponsors: Erasmus Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo ® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Conditions: Advanced Melanoma Interventions: Drug: BCD-263; Drug: Opdivo Sponsors: Biocad Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
A Double-Blind, Randomized Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo ® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Conditions: Advanced Melanoma Interventions: Drug: BCD-263; Drug: Opdivo Sponsors: Biocad Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery
Conditions: Squamous Cell Carcinoma of the Oropharynx; Squamous Cell Carcinoma, Unknown Primary Interventions: Device: Versius Surgical System Sponsors: CMR Surgical Ltd; Liverpool University Hospitals NHS Foundation Trust; Sintesi Research S.r.l. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Tirbanubulin (Klisiry ®) in the Treatment of Basal Cell Carcinoma
Conditions: Cell Carcinoma Interventions: Drug: Tirbanibulin Sponsors: Centre Hospitalier Universitaire de Nice Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Conditions: Advanced Melanoma Interventions: Biological: IMC-F106C; Biological: Nivolumab; Biological: Nivolumab + Relatlimab Sponsors: Immunocore Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
Conditions: Head and Neck Cancer; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck Interventions: Drug: Xevinapant; Drug: Carboplatin; Drug: Paclitaxel; Radiation: Radiation Therapy Sponsors: University of Chicago; EMD Serono Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas
Conditions: Esophageal Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma Interventions: Drug: Camrelizumab; Drug: Dalpiciclib 100mg; Drug: Dalpiciclib 150mg Sponsors: West China Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma
Conditions: Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable Interventions: Drug: Cetuximab; Drug: Zimberelimab; Drug: Docetaxel; Drug: Cisplatin Sponsors: Xuekui Liu Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Sponsors: Hebei Medical University Fourth Hospital; Handan Central Hospital; Xingtai People ' s Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Conditions: Metastatic Penile Squamous Cell Carcinoma; Stage III Penile Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Unresectable Penile Squamous Cell Carcinoma Interventions: Drug: Enfortumab Vedotin Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) Interventions: Drug: Netopitam Palonosetron capsules and dexamethasone Sponsors: Sichuan Cancer Hospital and Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
